We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





EUROMEDLAB 2022 Showcases Breakthrough Technologies and Cutting Edge Scientific Advances in Clinical Lab Diagnostics

By Carolyn Moody, RN - News Editor
Posted on 11 Apr 2022

The 24th European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB 2022) saw exhibitors displaying innovations in clinical laboratory diagnostic technologies and offering attendees a hands-on experience with the latest instruments, machines and equipment. More...

The five-day event held from 10th-14th April 2022 in Munich, Germany brought together scientists, laboratory specialists, clinicians, and industry participants in the field of clinical chemistry and laboratory medicine. The show attracted more than 3,000 active participants from across the world, and a number of international speakers and key opinion leaders were invited to address front-edge topics in diagnostic technologies, health care and scientific advances. Among the attendees were private and hospital laboratories, biologists, technicians, biomedical engineers and students.

Following its biannual pattern, EUROMEDLAB had originally been scheduled to take place in late November 2021. However, due to the critical pandemic situation at the venue – Munich in Bavaria, Germany – at that time, the congress was postponed to 10th-14th April 2022, prioritizing the health and safety of all visitors and exhibitors over other aspects. The congress was a hybrid event, with selected symposia and the opening and closing ceremony also held virtually. All COVID-19 restrictions to enter the Congress Centre had been cancelled, allowing all participants and visitors to freely access the Congress Centre and visit EUROMEDLAB. The importance of the live experience was reflected in the impressive reservation numbers. The floorspace of the 10,000-m2 Hall C1 and the ICM foyer was completely sold out and the number of research projects increased as compared to EUROMEDLAB 2020 with a total of 900 scientists submitting their abstracts as compared to 720 for the previous event. As such, the congress continued to grow in importance as a European hotspot for the science industry.

During the congress, attendees were able to experience the outstanding scientific program, which featured innovative and diverse educational opportunities that incorporated the best of clinical laboratory medicine and in vitro diagnostics, including lectures, symposia, recent advancements in clinical practice and science, poster presentations, and much more. A broad range of international speakers, key opinion leaders and stakeholders brought front-edge topics in health care, diagnostic technologies, scientific advances and professional matters to life. Special emphasis was placed on technological advancements, as the meeting aimed to connect the latest technological breakthroughs in diagnostic laboratory technology with the best minds in laboratory medicine to help attendees learn and implement the latest and greatest in clinical laboratory science, technology, and medicine. Attendees were also able to access a lively industry exhibition floor featuring the latest products and developments in diagnostic technologies brought by leading manufacturers. For those who were unable to able to attend the event in person, the show offered a brand-new format of interacting virtually with companies during the conference through the “Exhibition Floor Walks.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.